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was associated with greater age, male sex, and longer QRS 
duration, and, in those with HeFREF, treatment with ami-
odarone or digoxin. Patients with heart failure in the longest 
PRc quartile had worse survival compared to shorter PRc 
quartiles, but PRc was not independently associated with 
survival in multivariable analysis. For patients without heart 
failure, shorter baseline PRc was independently associated 
with worse survival.
Conclusion PRc prolongation is common in patients with 
HeFREF or HeFNEF and associated with worse survival, 
although not an independent predictor of outcome. The 
results of clinical trials investigating the therapeutic poten-
tial of shortening the PR interval by pacing are awaited.
Keywords First-degree heart block · Heart failure · PR 
interval
Abbreviations
CRT  Cardiac resynchronization therapy
eGFR  Estimated glomerular filtraion rate
HeFNEF  Heart failure with normal ejection fraction
HeFREF  Heart failure with reduced ejection fraction
LBBB  Left bundle branch block
LVEF  Left ventricular ejection fraction
NT-ProBNP  Amino-terminal pro-B-type natriuretic 
peptide
NYHA  New York Heart Association
TSH  Thyroid stimulating hormone
Introduction
Abnormal myocardial function is often accompanied by dis-
turbances in electrical conduction. Patients with heart failure 
with reduced ejection fraction (HeFREF) have a substantial 
Abstract 
Aims To determine the prevalence, incidence, predictors, 
and prognostic implications of PR interval prolongation in 
patients referred with suspected heart failure.
Methods and results Consecutive patients referred with 
suspected heart failure were prospectively enrolled. After 
excluding patients with implantable cardiac devices and 
atrial fibrillation, 1420 patients with heart failure and 
reduced ejection fraction (HeFREF) [age: median 71 (inter-
quartile range IQR 63–78) years; men: 71%; NT-ProBNP: 
1319 (583–3378) ng/L], 1094 with heart failure and normal 
ejection fraction (HeFNEF) [age: 76 (70–82) years; men: 
47%; NT-ProBNP: 547 (321–1171) ng/L], and 1150 with-
out heart failure [age: 68 (60–75) years; men: 51%; NT-
ProBNP: 86 (46–140) ng/L] were included. The prevalence 
of first-degree heart block [heart rate corrected PR interval 
(PRc) > 200 ms] was higher in patients with heart failure 
(21% HeFREF, 20% HeFNEF, 9% without heart failure). 
In patients with HeFREF or HeFNEF, longer baseline PRc 
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prevalence and annual incidence of QRS prolongation [1, 
2], both of which are associated with worse outcomes [2, 3]. 
However, there are few reports on the prevalence, incidence, 
and prognostic significance of the PR interval in ambula-
tory patients with chronic heart failure [4–6]. Analyses from 
studies in the general population have shown that PR interval 
prolongation is associated with increased risk of atrial fibril-
lation, pacemaker implantation, and mortality [7–10].
Most available data in heart failure relate to patients 
undergoing device implantation rather than coming from 
an unselected population [7]. Kronborg et al. reported that 
in 659 patients undergoing CRT implantation, 47% had first-
degree heart block, and that a long native PR interval was 
an independent predictor of all-cause and cardiac mortal-
ity [11]. In CARE-HF, a longer native PR interval at base-
line and longer PR interval at 3 months (paced PR for the 
CRT group and native PR for the control group) predicted 
both all-cause mortality and urgent hospitalisation for heart 
failure even after adjusting for CRT [5]. In patients with 
advanced heart failure, up to half of arrhythmic deaths may 
be bradycardic in origin, including high degree atrioven-
tricular block [12–14].
The introduction of cardiac resynchronisation therapy 
(CRT) has focussed interest on QRS duration and mor-
phology in patients with heart failure. Although CRT was 
originally conceived by many as a treatment for ventricu-
lar dyssynchrony, imaging studies have cast doubt on this 
hypothesis, leaving considerable doubt about precisely how 
CRT exerts benefit. Indeed, it may be that the predominant 
mechanism of benefit of CRT varies from one patient to the 
next and over time, and might include reduction of atrioven-
tricular delay. Recent reports [6, 15, 16] suggest that PR pro-
longation, a potential surrogate for greater atrioventricular 
delay, might also be a target for CRT.
The aim of the present analysis was to describe the prev-
alence, incidence, predictors, and prognostic implications 
of a prolonged PR interval in patients with suspected heart 
failure and, if confirmed, with or without a reduced left ven-
tricular ejection fraction (LVEF).
Methods
Ethics approval
The investigation conforms with the principles outlined in 
the Declaration of Helsinki. It was approved by the Hull 
and East Yorkshire Research Ethics Committee (Heart Care 
Study ELSY 2642). All subjects gave written informed 
consent.
Participants
Consecutive patients referred with suspected heart failure 
to a community heart failure clinic between 2001 and 2014 
were enrolled. Only patients in sinus rhythm on their base-
line electrocardiogram who did not have a ventricular pac-
ing device were included in the analysis. Heart failure with 
reduced ejection fraction (HeFREF) was defined as the pres-
ence of symptoms compatible with the diagnosis of heart 
failure and impaired left ventricular (LV) systolic function 
measured as an LVEF < 45% on echocardiography where 
possible and estimated visually when not. Heart failure with 
normal ejection fraction (HeFNEF) was defined as the pres-
ence of symptoms compatible with the diagnosis of heart 
failure with LVEF ≥ 45% and, for these patients in sinus 
rhythm, an amino-terminal pro-B-type natriuretic peptide 
(NT-ProBNP) ≥ 220 ng/mL. Patients with an LVEF ≥ 45% 
and an NT-ProBNP < 220 ng/mL were considered not to 
have heart failure.
Electrocardiographic intervals were obtained from auto-
mated analysis of the surface electrocardiogram (ECG). The 
only exclusion criteria were the inability to provide informed 
consent, pregnancy, atrial fibrillation, and an implanted 
cardiac device, even if not pacing at the time of the ECG 
recording, because the effect that pacing has on native ECG 
intervals is uncertain. For patients who received a cardiac 
device during follow-up, survival curves were censored at 
the time of implant (i.e., the patient was treated as lost to 
follow-up thereafter). Patients with paroxysmal atrial fibril-
lation who were in sinus rhythm on the baseline electrocar-
diogram were included in the analysis.
Clinical assessment
Baseline characteristics included medical history, therapy, 
height, weight and blood pressure, blood tests [standard 
haematology and biochemistry tests, thyroid stimulating 
hormone (TSH), and NT-ProBNP], and echo- and electro-
cardiographic data. Echocardiographic information included 
LVEF and the presence and severity of mitral regurgitation. 
Patients with diabetes included those managed by diet-alone 
or with insulin or other hypoglycaemic agents. Patients with 
the previous myocardial infarction, coronary artery bypass 
surgery, or positive tests for ischaemia were considered to 
have ischaemic heart disease (IHD). Cerebrovascular disease 
was defined as patients with a history of ischaemic stroke 
or transient ischaemic attack. The estimated glomerular 
filtraion rate (eGFR) was calculated using the abbreviated 
modification of the diet in renal disease (MDRD) equation 
[17].
Clin Res Cardiol 
1 3
Definition of PRc
Automated 12-lead ECG interval measurements were used 
to measure heart rate, PR, QRS, and QT intervals. PR 
interval reported was the longest measured PR interval in 
any lead. The PR interval duration changes with heart rate 
(longer PR interval at faster heart rates). Heart rate changes 
continually, therefore, to compare PR intervals taken at dif-
ferent heart rates, an adjustment is made (PRc) using a previ-
ously published formula [18]. We used PRc throughout our 
analysis, except in the hazard ratio analysis, where baseline 
heart rate is independently associated with worse survival in 
some groups, and for this reason, we present heart rate and 
unadjusted PR as separate variables. QT interval was also 
corrected for heart rate using Bazett’s formula [19]. First-
degree heart block was defined as PRc interval > 200 ms.
Follow‑up
Follow-up for all patients was censored at the last point of 
contact in primary or secondary care to avoid unreported 
deaths due, for instance, to emigration out of the region. 
Patients diagnosed with HeFREF were routinely given fol-
low-up appointments at 4 and 12 months with other visits 
as clinically indicated. Patients in whom the diagnosis of 
heart failure was excluded, as well as many patients with 
HeFNEF, were discharged and followed up only through 
electronic primary and secondary care health records which 
usually did not include electrocardiographic data. Accord-
ingly, electrocardiographic data during follow-up were only 
available for the patients with HeFREF.
Statistical analysis
Data are presented as median and interquartile range (IQR). 
Categorical data are presented as numbers and percentages. 
Differences between two independent groups of continuous 
data were tested using the independent t test. The Chi-square 
test was used for comparisons between independent groups 
of categorical data and a one-way ANOVA was used to com-
pare more than two independent groups of continuous data. 
For paired samples, the paired t test was used for continuous 
data. For categorical data with two or more categories, the 
McNemar’s test and the marginal homogeneity non-paramet-
ric test were used, respectively. For comparisons across PRc 
quartiles, trend statistical tests were used. SPSS (version 22) 
statistical computer package was used for data analysis.
The distribution of NT-ProBNP and TSH was skewed; 
we, therefore, used non-parametric tests to compare groups 
of continuous data and log-transformed NT-ProBNP and 
TSH data to satisfy the assumptions of the models.
Pearson correlation coefficients were used to observe 
the correlation between baseline variables in patients with 
HeFREF. Multiple linear regressions were used to identify 
variables associated with PRc interval and the Cox regres-
sion model was used to identify the variables associated with 
all-cause mortality. Only the significant variables identified 
using univariable analysis were used in the multivariable 
Cox regression models. We used two-tailed tests at a sig-
nificance level of 0.05.
Results
Of 2333 patients with HeFREF, 1950 with HeFNEF, and 
1193 without heart failure, respectively, 913 (39%), 856 
(44%), and 43 (4%) were excluded, mainly because of atrial 
fibrillation or an implanted device (Fig. 1). This left 1,420 
patients with HeFREF, 1094 with HeFNEF, and 1150 with-
out heart failure for the analysis (Table 1). Patients with 
HeFREF were younger, more likely to be men and had lower 
body surface area compared to those with HeFNEF. Patients 
without heart failure were slightly younger than in the other 
two groups. On average, compared to those with HeFNEF, 
patients with HeFREF had a faster heart rate, longer PRc, 
QRS, and QTc intervals and lower systolic and diastolic 
blood pressures, but eGFR and plasma TSH and mortality 
at 12 months were similar.
Amongst patients with HeFREF, 21% had a PRc > 200 ms 
compared to 20% of patients with HeFNEF (P = 0.33) and 
9% of those without heart failure (P < 0.001) (Supporting 
Fig. 1A), but the proportions with a PRc > 230 ms were sub-
stantially lower, 5, 7, and 2%, respectively. With increasing 
quartile of PRc duration, in each diagnostic group, a higher 
proportion of patients were aged > 65 years and men and 
median QRS duration increased (Table 2 and Supporting 
Tables 1, 2). Patients with HeFREF and longer PRc were 
also in a worse New York Heart Association class, which 
had worse left ventricular systolic function and greater use 
of loop diuretics (Table 2). Patients with HeFNEF and longer 
PRc had greater use of loop diuretics (Supporting Table 1).
Variables associated with a long PR interval
In all diagnostic groups, heart rate was inversely related to 
QT, PR, and QRS intervals (Supporting Table 3). PRc corre-
lated weakly with QRS (R2 = 0.04; P < 0.001) and to a lesser 
extent with QTc duration (R2 = 0.005; P = 0.01) but not heart 
rate (Supporting Table 3).
In patients without heart failure, longer PRc was posi-
tively correlated with a history of paroxysmal atrial fibril-
lation (1% had paroxysmal atrial fibrillation in the lowest 
PRc quartile compared to 5% in the highest PRc quartile; 
P = 0.03; data not shown). This association was not present 
in patients with heart failure.
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In a multivariable linear regression model, in patients 
with HeFREF, longer PRc interval was associated with 
greater age and male sex, longer QRS duration, and prescrip-
tion of digoxin or amiodarone (Table 3). In patients with 
HeFNEF, longer PRc interval was associated with greater 
age and male sex, longer QRS duration, and prescription 
of β-blockers (Table 3). In patients without heart failure, 
longer PRc interval was associated with greater age and dia-
betes, longer QRS duration, lower eGFR, and prescription 
of β-blockers.
One‑year follow‑up in patients with HeFREF
Paired assessments at baseline and 1 year were available for 
751 patients with HeFREF (Supporting Table 4); 171 had 
died, 24 developed atrial fibrillation, 38 had an implanted 
device, and 436 did not have a repeat electrocardiogram. 
Twenty-seven patients who developed AF at 1 year had 
an average baseline PRc of 179 ms, while the 38 patients 
requiring implantation of any cardiac device had an average 
PRc of 184 ms.
After 1 year, more patients were on heart failure medica-
tion compared to baseline, and LVEF had risen, New York 
Heart Association class and LV function had improved, 
NT-ProBNP had declined, and systolic and diastolic blood 
pressures had fallen. There was a decline in eGFR. Median 
PRc interval increased slightly further over 1 year [173 ms 
(156–193) to 176 ms (158–197); P < 0.001; Supporting 
Table 4]. The prevalence of first-degree heart block was sim-
ilar at baseline (17%) and 1 year (20%; P = 0.33); 39 patients 
with first-degree heart block at baseline had normal values 
by 1 year, while 52 patients developed new first-degree 
heart block. PRc duration increased by ≥ 5% in 262 (35%) 
patients with HeFREF, while it decreased by ≥ 5% in 161 
(21%) (Supporting Fig. 1B-C). Change by more than one 
quartile was rare (Supporting Fig. 1C). Only patients with 
a documented ECG at 1 year were included in this analysis. 
This may have resulted in selection bias.
Survival in patients with HeFREF
During a median follow-up of 3.9 years (IQR: 1.6–7.1), with 
follow-up censored at the time of death, 627 (44%; ~11% 
per annum) patients died (Fig. 2a). Patients in the highest 
baseline PRc quartile had a worse survival compared to all 
other quartiles. In a Cox regression model, baseline variables 
independently associated with worse survival were: increas-
ing log[NT-ProBNP], age, and NYHA class; and decreasing 
diastolic blood pressure and eGFR and the use of digoxin 
but neither PR nor PRc (Table 4).
Survival was worse in those with first-degree heart block 
in the second and subsequent years of follow-up especially if 
PRc increased between baseline and the first year (Support-
ing Fig. 2). β-blockers were started in 209 patients between 
Fig. 1  Patient eligibility flow diagram
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Table 1  Baseline demographic and clinical characteristics
Missing
N
 HeFREF
(N = 1420)
 HeFNEF
(N = 1094)
 Not HF
(N = 1150)
P value
HeFREF 
vs. Not 
HF
P value
HeFREF 
vs. HeF-
NEF
P value
HeFNEF 
vs. Not 
HF
P value
All groups
Age (years) – 71 (63–78) 76 (70–82) 68 (60–75) < 0.001 < 0.001 < 0.001 < 0.001
Men (%) – 1005 (71) 516 (47) 584 (51) < 0.001 < 0.001 0.156 < 0.001
NYHA class (%) 2/17/161
 I 212 (15) 325 (30) 488 (49) < 0.001 < 0.001 < 0.001 < 0.001
 II 708 (50) 493 (46) 369 (37)
 III 457 (32) 244 (23) 124 (13)
 IV 41 (3) 15 (1) 8 (1)
Diabetes (%) 2/3/4 356 (25) 287 (26) 259 (23) 0.12 0.36 0.06 0.13
Ischaemic heart disease 
(%)
2/7/15 932 (66) 476 (44) 244 (22) < 0.001 < 0.001 < 0.001 < 0.001
Cerebrovascular dis-
ease (%)
2/7/15 100 (7) 68 (6) 40 (4) < 0.001 < 0.001 0.01 0.001
Body surface area  (m2) 6/7/4 1.91 (1.73–2.08) 1.85 (1.71–2.04) 1.95 (1.78–2.11) < 0.001 0.01 < 0.001 < 0.001
Systolic BP (mmHg) 13/3/21 129 (114–147) 149 (131–167) 147 (132–162) < 0.001 < 0.001 0.06 < 0.001
Diastolic BP (mmHg) 13/3/21 76 (66–84) 78 (70–88) 83 (75–91) < 0.001 < 0.001 < 0.001 < 0.001
Heart rate (bpm) – 73 (63–86) 68 (59–78) 69 (60–79) < 0.001 < 0.001 0.18 < 0.001
QRS (ms) 6//1/4 112 (96–140) 92 (84–106) 90 (82–98) < 0.001 < 0.001 < 0.001 < 0.001
QRS ≥ 150 ms (%) 6//1/4 249 (18) 51 (5) 18 (2) < 0.001 < 0.001 < 0.001 < 0.001
PR (ms) – 172 (154–194) 168 (152–192) 162 (148–180) < 0.001 0.53 < 0.001 < 0.001
PRc (ms) – 174 (157–196) 168 (151–192) 163 (147–179) < 0.001 0.03 < 0.001 < 0.001
QT (ms) 19/19/6 413 (380–446) 406 (384–431) 396 (372–416) < 0.001 < 0.001 < 0.001 < 0.001
QTc (ms) 19/19/6 453 (422–483) 429 (410–452) 418 (401–441) < 0.001 < 0.001 < 0.001 < 0.001
TSH (mIU/L) 117/91/196 1.6 (1.0–2.5) 1.7 (1.1–2.5) 1.6 (1.0–2.3) 0.04 0.37 0.01 0.02
eGFR (1.73 mL/min/
m2)
3/2/12 62 (47–77) 61 (47–75) 75 (63–88) < 0.001 0.15 < 0.001 < 0.001
NT-ProBNP (ng/L) 436/8/139 1319 (583–3378) 547 (321–1171) 86 (46–140) < 0.001 < 0.001 < 0.001 < 0.001
Ejection fraction by 
Simpson’s
564/523/491 33 (27–37) 54 (48–61) 59 (54–64) < 0.001 < 0.001 < 0.001 < 0.001
LV systolic dysfunc-
tion (%)
–
 Normal–trivial 0 820 (75) 1151 (100) < 0.001 < 0.001 < 0.001 < 0.001
 Mild 0 274 (25) 0
 Mild–moderate 849 (60) 0 0
 >Moderate 571 (40) 0 0
Mitral regurgita-
tion > mild (%)
27/17/161 447 (32) 124 (13) 27 (2) < 0.001 < 0.001 < 0.001 < 0.001
Medication at initial 
visit
β-blocker (%) 14/18/55 862 (61) 550 (51) 285 (26) < 0.001 < 0.001 < 0.001 < 0.001
 ACE-I (%) 14/18/55 1019 (72) 532 (49) 325 (30) < 0.001 < 0.001 < 0.001 < 0.001
 ARB (%) 14/18/55 133 (9) 161 (15) 128 (12) 0.07 < 0.001 0.02 < 0.001
 MRA (%) 14/18/55 422 (30) 95 (9) 22 (2) < 0.001 < 0.001 < 0.001 < 0.001
 Amiodarone (%) 6/18/36 66 (5) 19 (2) 6 (0.5) < 0.001 0.001 < 0.001 < 0.001
 Digoxin no. (%) 6/18/36 118 (8) 40 (4) 9 (0.8) < 0.001 < 0.001 < 0.001 < 0.001
 Loop Diuretic (%) 8/18/3 993 (70) 557 (52) 249 (22) < 0.001 < 0.001 < 0.001 < 0.001
 Ivabradine (%) 14/18/55 5 (0.4) 2 (0.2) 0 0.07 0.35 0.5 0.14
 1 year mortality (%) – 171 (12) 76 (10) 8 (1) < 0.001 0.13 < 0.001 < 0.001
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baseline and 1 year. Of these, 46 had first-degree heart block 
at baseline and a further 24 (12%) developed it by 1 year. 
There was no interaction between commencing β-blockers, 
new first-degree heart block at 1 year and survival.
Survival in patients with HeFNEF
During a median follow-up of 3.7 years (IQR: 1.7–7.4), with 
follow-up censored at the time of death, 444 (41%; ~11% per 
annum) patients died. Patients in the highest baseline PRc 
quartile had a worse survival compared to all other quar-
tiles (Fig. 2b). In a Cox regression model, baseline variables 
independently associated with worse survival in HeFNEF 
were: increasing log[NT-ProBNP], male sex, higher New 
York Heart Association class, and age. Neither PR nor PRc 
was independent predictors of outcome. The presence of 
diabetes, a lower body surface area, and the use of a loop 
diuretic or digoxin were also associated with worse survival 
(Table 4). A slower baseline heart rate was associated with 
better survival.
Survival in patients without heart failure
During a median follow-up of 7.9 years (IQR 3.2–11.2), 
only 190 (17%; 2% per annum) patients died. Follow-up was 
much longer than in the heart failure groups because of low 
mortality leading to low rates of censorship due to death. On 
an unadjusted analysis of quartiles, shorter PRc and a faster 
heart rate were independently associated with worse sur-
vival (P = 0.02 each). Increasing log[NT-ProBNP], male sex 
and increasing age were associated with worse survival in 
patients without heart failure as was worse functional class 
(132 patients in NYHA III/IV) and the use of loop diuret-
ics (249 patients). Of patients taking loop diuretics (249 
patients), 73 died (29%; 4% per annum). Of patients with an 
NT-ProBNP between 125 and 220 ng/L (310 patients), 80 
died (26%; 3% per annum). Many patients had chronic lung 
disease accounting for symptoms.
Device implantation
During follow-up, 144 patents with HeFREF were implanted 
with CRT with or without a defibrillator. Twenty-nine 
patients were implanted with defibrillator alone, while 36 
patients had a pacemaker. Thirty-six patients with HeFNEF 
required a pacemaker during follow-up as did 20 patients 
without heart failure. Increasing PR and QRS interval dura-
tion as well as advancing age were associated with a greater 
risk of pacemaker implantation (Supporting Table 5).
Discussion
This study is the first large epidemiological study to report 
the prevalence and predictors of a long PR interval in 
patients with heart failure. We found that modest increases 
in PR duration are common in heart failure with or without 
a reduced LVEF.
The prevalence of first-degree heart block in patients with 
HeFREF was 21%. In the subgroup of patients with moder-
ate–severe LV dysfunction and QRS ≥ 130 ms (N = 227), the 
prevalence on first-degree heart block was 29%. This is con-
sistent with the previous studies in patients with heart fail-
ure, LVEF < 35%, and left bundle branch block undergoing 
CRT, where the prevalence of first-degree heart block was 
reported to be between 26–52% [5, 6, 20]. Amongst patients 
with HeFNEF and QRS ≥ 130 ms (N = 115), the prevalence 
of first-degree heart block was even higher (40%).
A long PR interval in heart failure is likely to reflect 
widespread electrophysiological abnormalities, including 
atrial enlargement and myocardial fibrosis, atrioventricular 
nodal conduction delay and/or bundle branch/Purkinje fibre 
conduction delay, altered autonomic tone, and the effects of 
pharmacological interventions [21]. Studies of animal mod-
els of heart failure have shown anatomical and ion channel 
changes in the atria and atrioventricular node associated 
with delayed atrioventricular conduction [22].
PRc was not an independent predictor of outcome in 
patients with heart failure. This adds to existing evidence on 
first-degree heart block in other populations. Data from the 
Finish Social Insurance Institution’s Coronary Heart Disease 
(CHD) Study showed no increased risk of mortality, hospi-
talisation, or incidence of atrial fibrillation, heart failure, or 
stroke with first-degree heart block in the general popula-
tion [23]. In contrast, the Framingham study reported an 
increased risk of atrial fibrillation, pacemaker implantation, 
Table 1  (continued)
Bold indicates significance at the 0.05 level
Continuous variables are presented as median (interquartile range), whereas categorical variables are expressed as percentage. P values are for 
differences between patients with HeFREF, HeFNEF, and those without heart failure. Pair-wise comparisons were performed using the inde-
pendent t test for continuous data (except for TSH and NT-ProBNP where the Mann–Whitney test was used) and the Chi-square test for categori-
cal data. The one-way ANOVA test was used for comparisons of continuous data across all groups (except for TSH and NT-ProBNP where the 
Kruskal–Wallis test was used) and the Chi-square test for categorical data
ACE-I angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, BP blood pressure, eGFR estimated glomerular filtration rate, 
MRA mineralocorticoid receptor antagonist, NYHA New York Heart Association, TSH thyroid stimulating hormone
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and death with PR interval prolongation at 20 years’ fol-
low-up [8]. In patients with stable coronary artery disease 
and normal ejection fraction, first-degree heart block was 
associated with increased mortality and hospitalisation for 
heart failure in one study [24].
Patients with heart failure and first-degree heart block 
undergoing CRT have worse prognosis compared to those 
Table 2  Baseline demographic and clinical characteristics of patients with HeFREF, classified by PRc quartiles
Bold indicates significance at the 0.05 level
Continuous variables are presented as median (interquartile range), whereas categorical variables are expressed as numbers (percentage). P val-
ues are for differences between PRc quartiles (columns 2, 3, 4, and 5). The one-way ANOVA linear trend test was used for comparisons of con-
tinuous data across groups and the Cochran’s Chi-square trend test for categorical data
ACE-I angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, BP blood pressure, eGFR estimated glomerular filtration rate, 
MRA mineralocorticoid receptor antagonist, NYHA New York Heart Association. See also Supporting Tables 1 and 2
PRc Q1 N = 355 PRc Q2 N = 355 PRc Q3 N = 355 PRc Q4 N = 355 P value
Age (years) 70 (61–77) 70 (61–77) 71 (63–78) 73 (65–79) < 0.001
Men, no. (%) 225 (63) 236 (67) 259 (72) 285 (81) < 0.001
NYHA class, no. (%)
 I 59 (17) 51 (14) 54 (15) 47 (13) 0.002
 II 193 (54) 180 (51) 171 (48) 164 (46)
 III 96 (27) 114 (32) 122 (35) 125 (36)
 IV 7 (2) 9 (3) 6 (2) 19 (5)
Diabetes, no. (%) 64 (18) 83 (23) 96 (27) 113 (32) 0.001
Ischaemic heart disease, no. (%) 232 (65) 232 (65) 228 (64) 240 (68) 0.64
Cerebrovascular disease, no. (%) 17 (5) 30 (8) 28 (8) 28 (8) 0.19
Body surface area  (m2) 1.86 (1.67–2.05) 1.90 (1.71–2.08) 1.91 (1.75–2.07) 1.95 (1.78–2.11) < 0.001
Systolic BP (mmHg) 130 (115–147) 129 (115–147) 130 (115–147) 128 (112–147) 0.69
Diastolic BP (mmHg) 75 (67–83) 75 (66–84) 78 (69–87) 75 (65–83) 0.89
Heart rate (bpm) 70 (60–84) 74 (64–87) 72 (62–86) 73 (62–86) 0.34
QRS (ms) 104 (92–134) 106 (96–136) 114 (98–142) 120 (104–148) < 0.001
QRS ≥ 150 ms (%) 44 (12) 51 (14) 69 (19) 88 (25) < 0.001
PR (ms) 144 (134–151) 164 (160–168) 182 (176–188) 210 (200–222) –
PRc (ms) 146 (136–152) 166 (162–170) 184 (178–189) 212 (203–224) –
QT (ms) 417 (382–446) 406 (374–440) 412 (385–449) 418 (384–452) 0.15
QTc (ms) 447 (419–478) 453 (421–482) 454 (422–486) 456 (424–484) 0.01
Thyroid stimulating hormone (mIU/L) 1.5 (1.0–2.4) 1.5 (1.0–2.3) 1.7 (1.0–2.6) 1.7 (1.1–2.7) 0.01
eGFR (1.73 mL/min/m2) 66 (50–81) 63 (48–79) 61 (46–77) 58 (44–71) < 0.001
NT-ProBNP (ng/L) 1311 (582–3045) 1048 (446–3331) 1400 (548–3350) 1751 (811–3915) 0.50
Ejection fraction by Simpson’s 32 (27–38) 33 (27–38) 33 (27–37) 32 (25–37) 0.19
Left ventricular dysfunction, no. (%) 0.02
 Normal–trivial – – – –
 Mild 0 0 0 0
 Mild–moderate 227 (64) 213 (60) 213 (60) 196 (55)
 >Moderate 128 (36) 142 (40) 142 (40) 159 (45)
Mitral regurgitation > mild 108 (31) 100 (29) 124 (36) 115 (33) 0.23
β-blocker, no. (%) 208 (60) 222 (63) 214 (61) 218 (61) 0.57
 ACE-I, no. (%) 259 (74) 254 (72) 251 (71) 255 (73) 0.72
 ARB, no. (%) 31 (9) 37 (10) 26 (7) 39 (11) 0.59
 MRA, no. (%) 87 (25) 109 (31) 115 (32) 111 (32) 0.05
 Amiodarone, no. (%) 14 (4) 9 (3) 14 (4) 29 (8) 0.005
 Digoxin, no. (%) 20 (6) 28 (8) 32 (9) 38 (11) 0.01
 Loop diuretic, no. (%) 234 (67) 237 (67) 246 (70) 276 (78) 0.001
 Ivabradine, no. (%) 3 (0.8) 1 (0.3) 0 1 (0.3) 0.16
 1 year mortality, no. (%) 36 (10) 49 (14) 36 (11) 49 (13) 0.34
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with a normal PR interval [25, 26]. However, patients with 
first-degree heart block may derive greater benefit from 
CRT compared to pharmacological therapy [15]. In the 
COMPANION trial, a PR interval > 200 ms was associ-
ated with a 41% increased risk of the composite outcome of 
all-cause mortality or heart failure hospitalisation in those 
assigned to pharmacological therapy but was not higher 
amongst patients assigned to CRT [6]. A post hoc analysis 
from MADIT-CRT suggested that patients who did not have 
LBBB but did have a long PR interval benefited from CRT, 
whereas those with a normal PR interval did not [15]. The 
HOPE-HF trial is currently testing whether CRT with atrio-
ventricular optimisation and His bundle pacing is beneficial 
in patients with heart failure and long PR interval without 
left bundle branch block [27].
In patients without heart failure, a short rather than a long 
PRc independently predicted increased mortality. This is in 
keeping with the previous findings in healthy population 
studies and in patients with coronary artery disease, suggest-
ing that a short PR interval may not be a benign finding [28, 
29]. It is unknown whether a short PR interval is a marker 
of underlying cardiac pathology (such as the presence of a 
concealed accessory pathway) or impaired autonomic/elec-
trotonic regulation in the atrioventricular node.
Prolongation of QRS is common in patients with heart 
failure and is associated with worse outcomes [2, 3]. We 
found that in patients with heart failure (with or without 
reduced ejection fraction), neither QRS nor PRc interval 
duration was independently associated with all-cause mor-
tality in models that included powerful prognostic markers 
such as age and NT-ProBNP. In the Korean heart failure 
registry (N = 1986), 16% of patients presenting with acute 
heart failure had first-degree atrioventricular block. The 
combination of first-degree atrioventricular block with a 
QRS duration ≥ 120 ms was associated with an increased 
risk of adverse outcomes, including all-cause mortality [4]. 
In our study, patients with PRc ≥ 200 ms and QRS ≥ 130 ms 
had worse survival compared to other groups (Supporting 
Fig. 3), but combined PRc/QRS duration was not an inde-
pendent predictor of mortality. Our study shows that similar 
to data from the general population [8], a long PR interval is 
associated with higher risk of simple pacemaker implanta-
tion in patients with heart failure who do not meet criteria 
for CRT or defibrillator.
β-blockade, amiodarone, and digoxin all prolong atrio-
ventricular conduction. Patients on amiodarone are likely to 
have experienced prior atrial or ventricular arrhythmias, and 
may be more likely to have severe underlying heart disease 
and conduction abnormalities. However, β-blockade was not 
associated with prolongation of the PRc interval in patients 
with HeFREF; the atrioventricular node may be insensitive 
to β-blockade-induced conduction delay in heart failure, pos-
sibly due to down-regulation of adrenergic receptors or a 
reduction in parasympathetic tone.
A long PR interval is associated with an increased risk 
of subsequently developing atrial fibrillation in the general 
population [30]. Our data support this finding in patients 
without heart failure, in whom longer PRc was positively 
correlated with a history of paroxysmal atrial fibrillation 
(1% in the first quartile of PRc had paroxysmal atrial fibril-
lation compared to 5% in the fourth quartile; P = 0.03; data 
not shown).
Study limitations
We used a single electrocardiogram to measure PR interval. 
The PR interval varies during the day and under different 
physiological conditions. We did not have 24-h monitoring 
Fig. 2  Survival in patients with HeFREF (a), HeFNEF (b), and without heart failure (c) according to baseline PRc quartile (PRc ranges shown 
in brackets are in milliseconds)
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data. Patients with severe conducting disease were excluded, 
because they had an implanted cardiac device. The definition 
of first-degree heart block as > 200 ms is arbitrary and for 
this reason, PR interval duration was used as continuous var-
iable in prognostic models. Due to the observational nature 
of this study, it is possible that unknown confounding factors 
may have affected our findings. We necessarily excluded 
patients with atrial fibrillation. At baseline, atrial fibrillation 
was common particularly in patients with normal ejection 
fraction, in whom the prevalence was 36% compared to 5% 
in patients with HeFREF. This finding is consistent with 
the previous reports [13] and suggests that atrial fibrillation 
might be a cause of HeFNEF. Patients with atrial fibrillation 
might have more severe atrioventricular conduction disease 
than patients in sinus rhythm, but it will be concealed. If so, 
we will have underestimated the true prevalence and conse-
quences of conducting system disease in patients with heart 
failure, especially those with normal ejection fraction.
Conclusions
A prolonged PR interval is common in patients with chronic 
heart failure regardless of left ventricular ejection fraction. 
Although patients with heart failure and a longer PRc have 
worse survival, PRc is not independently associated with 
prognosis. Whether PR prolongation is a therapeutic target 
for pacing therapies in patients with heart failure is currently 
being tested in randomised trials.
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